Delivery 7–10 daysVyvgart (efgartigimod alfa) injection
The cart and your orders live in your personal account — checkout requires signing in.
Description
💊 Prescription first-in-class FcRn blocker for generalised myasthenia gravis in adults, primarily those with acetylcholine receptor antibodies.
▪︎ Efgartigimod alfa 400 mg/20 mL single-dose vial for intravenous infusion (a subcutaneous form also exists)
▪︎ Manufacturer: argenx
▪︎ FDA approval: December 2021; indication extended to CIDP in 2024
🔬 How it works: an ordinary blood protein lasts hours, but IgG antibodies last about three weeks — because the neonatal Fc receptor (FcRn) intercepts IgG inside the cell and carries it back into the blood instead of letting it be destroyed. That system does not distinguish a protective antibody from one attacking the acetylcholine receptor. Efgartigimod is an antibody fragment that binds FcRn more tightly than IgG does, occupying the rescue slots so that pathogenic antibodies are degraded. The result resembles plasma exchange without vascular access or a machine. 📊 Evidence: ADAPT (Lancet Neurol 2021) in 167 patients — among those with acetylcholine receptor antibodies, an MG-ADL response in the first cycle in 68% versus 30% on placebo (odds ratio 4.95; p<0.0001), with adverse events less frequent than on placebo (77% versus 84%). ADAPT-SC (Neurotherapeutics 2024) showed the subcutaneous form non-inferior for IgG reduction.
⚠️ Prescription-only, prescribed by a neurologist. Given in cycles of four weekly administrations with a break, restarted as symptoms return rather than on a fixed schedule. All IgG falls, not just the harmful kind, so vaccination is planned in advance and infections are assessed carefully. In the trials it was added to existing therapy, not substituted for it.
📦 Ordered on request via chat — availability and current price are confirmed by the administrator.
